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Abstract—Precision metabolomics and quantification for cost-
effective, rapid diagnosis of disease are key goals in personalized 
medicine and point-of-care testing. Presently, patients are 
subjected to multiple test procedures requiring large laboratory 
equipment. Microelectronics has already made modern computing 
and communications possible by integration of complex functions 
within a single chip. As More than Moore technology increases in 
importance, integrated circuits for densely patterned sensor chips 
have grown in significance. Here, we present a versatile single 
CMOS chip forming a platform to address personalized needs 
through on-chip multimodal optical and electrochemical detection 
that will reduce the number of tests that patients must take. The 
chip integrates interleaved sensing subsystems for quadruple-
mode colorimetric, chemiluminescent, surface plasmon resonance 
and hydrogen ion measurements. These subsystems include a 
photodiode array and a single photon avalanche diode array, with 
some elements functionalized to introduce a surface plasmon 
resonance mode. The chip also includes an array of ion sensitive 
field effect transistors. The sensor arrays are distributed 
uniformly over an active area on the chip surface in a scalable and 
modular design. Bio-functionalization of the physical sensors 
yields a highly selective simultaneous multiple-assay platform in a 
disposable format. We demonstrate its versatile capabilities 
through quantified bioassays performed on-chip for glucose, 
cholesterol, urea and urate, each within their naturally occurring 
physiological range. 
 
Index Terms— CMOS, multimodality, diagnosis, biomarker, 
detection, colorimetric, chemiluminescence, pH measurements, 
surface plasmon resonance, nanodiscs, plasmon filters, SPAD, 
Photodiode. ISFET. 
I. INTRODUCTION 
ptical and electrochemical sensing techniques are widely 
used in biomedical science and clinical medicine. 
Colorimetric analysis [1], chemiluminescence [2], fluorescence 
[3], surface plasmon resonance (SPR) [4], potentiometry and 
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amperometry [5] are commonly employed optical and 
electrochemical modalities for biosensing and quantification. 
Both have been employed in clinical diagnostics, DNA 
sequencing [2], [6], immunoassays [5], [7], metabolite 
quantification [8]–[10], and protein detection [11], [12] for the 
identification of diseases at an early stage using biomarkers 
[13]. 
The diversity in the range of biomarkers is conventionally 
addressed by the use of multiple single-mode, bench-top 
laboratory instruments [14]. For example, detecting a specific 
biomarker (e.g. a metabolite) using a colorimetric assay 
requires a spectrophotometer comprising an illumination source 
and a photosensitive light detector to measure enzymatic 
activity by means of a colour change [15]. A 
chemiluminescence assay does not require an illumination 
source but needs an instrument with a highly sensitive light 
detector such as a charge-coupled device (CCD) or a 
photomultiplier tube (PMT) to measure weak light emission 
[16]. Surface plasmon resonance (SPR) provides a further 
optical modality to detect biological or chemical activities by 
measuring localized changes in refractive index at the 
functionalized surface of a metal such as gold when a target 
analyte is present [4]. 
In electrochemical sensing, ionic concentrations are measured 
either by potentiometry e.g. with a glass electrode for pH 
measurements, or voltammetry using a potentiostat, to induce 
and measure charge transfer reactions [17], [18]. These 
instruments use electrodes to detect metabolites; for example, 
blood glucose self-monitoring devices use enzymes to produce 
hydrogen ions in proportion to the metabolite concentration [8], 
[19]. Presently, all these modalities rely on discrete and 
specialized apparatus. However, complementary metal oxide 
semiconductor (CMOS) technology presents a new alternative, 
with integration of many of the sensor and electronic circuits 
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required on a single chip [20]–[24]. This opens a route to 
bespoke, specific diagnosis and disease management at low-
cost and readily deployed outside a specialized laboratory. 
Integration of multiple measurement modalities on a single chip 
enables multiple biomarker tests from a single sample, with the 
potential to accelerate and improve care pathways and to 
increase convenience for patients. 
CMOS microelectronics is the foundation of modern 
computing and communication technology, facilitating mass 
manufacture of today’s sophisticated consumer and commercial 
systems [25]. Research has demonstrated that CMOS 
technology is versatile, comprising a rich materials palette 
capable of exploitation in unconventional markets. Careful 
design and advanced fabrication techniques have allowed 
CMOS to address applications such as chemical sensing, gas 
detection and genomics [26]–[29]. Here we show that 
innovative design and technology integration create new 
opportunities to exploit CMOS technology in metabolomics 
and biomarker measurement. Unlike genomics that reveal an 
individual’s innate propensity towards disease, we focus on 
metabolomics, or phenotypical markers, that have proven utility 
in monitoring the individual’s current physiological state [14], 
[30]–[32].  
Thousands of metabolites can be found in human serum 
alone, many of which can be used as biomarkers for diseases 
and functional evaluation [31]. However, the measurement 
challenge is distinct from that of genetic sequencing since the 
physicochemical properties of metabolites are diverse and 
dynamic concentration varies over many orders of magnitude 
in human body fluids. Highly differentiated sensors are required 
using optical and electrochemical modalities and metabolite 
specific biofunctionalization of sensors in an array.  
II. DISPOSABLE MULTIMODAL CMOS PLATFORM 
We have used a CMOS process, for the first time to the 
authors’ knowledge, to allow interleaving of four widely used 
laboratory measurement modalities: colorimetry, 
chemiluminescence, SPR and hydrogen ion (H+) measurement. 
The data presented exploit devices made without deviation 
from standard CMOS device technology. Specific 
measurements for biochemical sensing are achieved after 
nanofabrication of optical structures and biofunctionalization in 
a post-foundry process step. 
The chip has two optical sensor arrays based on photodiodes 
(PDs) and single photon avalanche diodes (SPADs). These are 
both implemented using the foundry technology without 
modification. The SPAD array is used for chemiluminescence 
detection since high sensitivity is required. In contrast, the 
colorimetric mode requires an illumination source, therefore the 
PD is suitable as it is not susceptible to saturation by ambient 
light. Enzyme-based assays coupled to dyes that change colour 
in the presence of the reaction products are exploited to quantify 
the metabolite turned over by the enzyme. The use of PDs and 
SPADs in combination extends the optical dynamic range, for 
the first-time allowing integration of colorimetric 
measurements for high concentration metabolites and 
chemiluminescence measurement for low concentration 
metabolites. 
Further physical functionalization of the sensors can be 
achieved by additional post-foundry nanofabrication on to 
either the PDs or the SPADs. Arrays of gold nanodiscs over an 
individual sensor fabricated in this manner exhibit SPR; when 
a fixed wavelength light source is applied, any change in the 
resonant wavelength caused by a change in the refractive index 
at the metal surface modifies the optical transmission of the 
nanodisc array and can be measured by the PDs or SPADs. In 
addition to the optical sensor arrays, the chip has an ion 
sensitive field effect transistor (ISFET) array selective for H+ to 
provide an electrochemical measurement capability for 
metabolite detection via proton release. 
The multi-sensor array chip forms a platform in which a 
wide-range of application-specific bioassays can be rapidly 
employed and used selectively with one of the integrated 
modalities. The use of an array for each modality offers the 
potential to selectively functionalize parts of the array for 
different assays. By so doing, we create the potential for a 
broad-spectrum diagnostic tool that will eliminate the need for 
multiple repeated procedures that cause patient discomfort and 
alarm. Fig. 1 illustrates the concept of the proposed portable 
platform with a disposable CMOS-based cartridge.  
III. SCALABLE MODULAR DESIGN OF THE CMOS CHIP 
The CMOS chip incorporates a 16 x 16 array of elements, 
each with three “pixels” for, respectively, a PD, a SPAD and an 
ISFET, giving 256 of each type of sensor in the array. This 
arrangement ensures an even distribution of sensors for each 
modality across the active area of the chip allowing a scalable 
modular design as illustrated in Fig. 2. In addition to the 
capacity to selectively functionalize parts of the array for 
different assays, the array can be used to exploit the statistical 
phenomenon of averaging signals from independent Gaussian 
noise sources, either over time or spatially, to improve the 
overall system sensitivity. The chip integrates addressing 
blocks to allow each sensor array to be controlled and operated 
independently or simultaneously as required, as shown in 
 
Fig. 1. Working principle of the prototype portable CMOS platform. The 
system comprises a disposable cartridge containing the CMOS chip and a 
reader connected to a tablet PC or Smart Phone. 
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Fig. 3. Whilst full operation of all aspects of the chip 
simultaneously is possible, the device integrates power-down 
switches (Fig. 3) for the SPAD and ISFET arrays to selectively 
manage and reduce power consumption. 
The PD pixel, Fig. 3, incorporates a P-N junction with a 
three-transistor (M1p, M2p and M3p) active photosensor 
design [33]. The pixel’s exposure is controlled by a global 
shutter input, Vrst. Depending on the integration time, a given 
photocurrent, Iph, corresponds to a given voltage, Vd, across the 
PD. The values of Vd for all pixels are measured and streamed 
to a single output pad using independent 4-bit row and column 
decoders.  
The SPAD pixel, incorporates a P-N junction with a high 
breakdown voltage operated in the Geiger mode at a reverse 
bias voltage, HV - VBias, above its breakdown voltage. The 
SPAD uses a transistor, M1S, to quench the avalanche process 
triggered by a photon incident on its active area, resulting in a 
stream of output pulses proportional in count-rate to the number 
of incident photons. The pulses drive a controlled inverter, M2S 
and M3S, and are then counted by a dedicated 16-bit counter 
outside the aperture of the array. The SPAD array is scanned 
using a rolling shutter scheme in which the 16 SPADs from 
each column are activated sequentially using a 4-bit address 
decoder, reducing power consumption. The column SPADs’ 
outputs are connected to 16 counters. A second decoder feeds 
their outputs sequentially into a 1-bit digital output via a 
serializer. All transistors in the SPAD array are isolated using a 
high voltage (HV) deep n-well to reduce crosstalk with other 
sensors. 
Half of the optical sensors are modified to make SPR sensors 
on-chip. Most SPR systems adopt the Kretschmann 
configuration, using a plane-polarized light with a fixed angle 
of incidence, and a CCD camera to detect the wavelength of 
light reflected from a gold sheet [34], [35]. Highly selective 
biomarker detection that involves binding to immobilized 
receptors is a common application of SPR in diagnostics, 
providing the perturbation to the refractive index at the gold 
surface that underpins the method [4]. For the on-chip SPR 
sensors, gold nanodisc optical filters were post-processed on to 
the PDs and SPADs located in alternate columns, resulting in 
an array of 128 filtered (even columns) and 128 unfiltered (odd 
columns) PDs and SPADs (Fig. 2). The post-processing 
fabrication steps and a detail of the fabricated structure is shown 
in Fig. 4 (a). The nanostructures were designed to have a fixed 
disc diameter and fixed pitch. These parameters, together with 
the refractive index of the sensor’s environment, determine the 
resonant wavelength of the nanostructures that collectively act 
as an optical band-stop filter. Au was chosen to create the 
plasmonic structures for its biocompatible properties and 
because it is a noble metal. The plasma frequency in Au occurs 
at approximately 450 nm. SPR effects that are used for sensing 
are strongest at longer wavelengths. Si photodiodes exhibit 
excellent sensitivity above 630 nm. The nanodiscs are also 
easier to fabricate for longer wavelengths owing to scaling. 
These considerations motivated our choice of dimensions. The 
resonance response of the filters was optimized using finite 
element analysis software (Multiphysics®, COMSOL Ltd, 
Cambridge, UK). The discs were 60 nm thick, 200 nm in 
diameter and the pitch was 450 nm. Prior to fabricating the 
nanodisc array, a 500 nm thick layer of SiO2 was deposited 
using plasma-enhanced chemical vapor deposition (PECVD), 
as shown in Fig. 4(a), (ii). The nanodiscs were selectively 
fabricated on alternate columns, with the other columns left 
blank. A poly(methyl methacrylate) (PMMA) bi-layer was 
patterned to create the nanodisc array using electron beam 
lithography, and developed with IPA:MIBK (3:1) (Fig. 4(a) 
 
Fig. 2. Layout of the CMOS chip integrating 16 x 16 elements: each 
integrates a SPAD, an ISFET and a PD with their readout circuits. Columns 
were alternatively patterned with Au nanodiscs to build SPR sensors. 
  
  
Fig. 3. Block diagram of the CMOS chip, showing the independent addressing 
and readout architectures of the multiple sensing techniques. The magnified 
section shows the schematic of the readout circuits of the three sensors: SPAD, 
PD and ISFET. 
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(iii)). 60 nm of gold was evaporated on top of 3 nm of Ti, for 
adhesion purposes (Fig. 4(a) (iv)). Finally, the resist and 
unwanted metal was removed by lift off in acetone to leave the 
final structure (Fig. 4(a) (v)). The resonant wavelength from 
simulation was 750 nm which agreed well with the 
experimental results from fabricated nanodiscs on a glass slide 
as shown in Fig. 5 (a). Further experiments were conducted as 
a feasibility study, using nanodiscs on glass to show a resonant 
wavelength shift as a function of different glycerol 
concentrations, as it is a well-documented refractive index 
marker (Fig. 5 (b)) [36]. 
The ISFET “pixel” (Fig. 3), uses a source follower 
configuration, M1i and M2i, where M1i is an ion sensitive 
transistor with its floating gate connected to a four-metal-layer 
stack in contact with the silicon oxide (SiO2) layer. The sensor 
determines the ionic concentration above the passivation layer 
by measuring the change in current resulting from a change in 
the threshold voltage of the transistor and the gate 
capacitance[37]. The circuit incorporates a transmission gate 
for column addressing. Scanning of the array is achieved with 
two 4-bit decoders addressing the columns and rows via a 16-
to-1 analog multiplexer located outside the array aperture. As 
for the SPAD array, the ISFET array incorporates the deep n-
well layer of the HV process to reduce crosstalk from other 
sensors (Fig. 4 (b)). 
The chip was fabricated using a commercially available HV 
CMOS 350 nm 4-metal process (H35, AMS, Premstaetten, 
Austria). The triple-well HV process not only enabled the use 
of high voltages for the SPAD’s Geiger mode, but it also 
allowed for the interleaved integration of separate sensor arrays, 
using individual circuit-isolating deep n-wells. Each sensor 
element is laid out in a 110 µm x 110 µm square; the SPAD, 
PD, and ISFET sensors comprise active areas of 314 µm2, 54 
µm2 and 484 µm2, respectively. The total area of the final array 
is 1.76 x 1.76 mm2. The chip has only 55 pads for power supply, 
control and output signals. Pads were only placed on two 
opposing sides of the CMOS chip so as to ease microfluidic 
channel integration. Separate power supply pads were used for 
each type of sensor and its accompanying circuits to ensure 
independent operation and manage the effective delivery of 
power. 
Chips fabricated in the AMS H35 process have a polyimide 
top layer preventing access to the desired ISFET passivation 
layer. Having different sensors interleaved in the array proved 
to be challenging in terms of post-processing fabrication for the 
ISFET since the SPAD’s doped regions could be affected by 
reactive ion etch steps.  An opening in the polyimide layer over 
the active area of each ISFET was therefore included in the 
design layout sent to the foundry. This opening comes at the 
cost of removing all the other passivation layers from the top 
metal layer (M4), including the Si3N4 and SiO2, as shown in 
 
Fig. 4. A cross-section of an element showing the SPAD, PD and ISFET implementation in the CMOS process and the post-processing fabrication steps for (a) an 
element of an even column patterned with nanodiscs on the chip surface and (b) an element of an odd column where a thin layer of SiO2 was selectively revealed 







 Fig. 5. (a) Simulated and measured transmission spectra of fabricated 
nanodiscs on a glass slide. (b) Measured resonant wavelength shift as a function 
of glycerol concentration of nanodiscs on a glass slide. 
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Fig. 4(b), (i). An additional SiO2 membrane layer was exposed 
under M4 by etching away the M4 aluminium (Al) as illustrated 
in Fig. 4 (b), (ii) using a wet etch process of 
H2O:H3PO4:HNO3:CH3COOH solution in the ratio 2:16:1:1. To 
protect the Al bond pad contacts, photoresist was spun on and 
an opening was created over the ISFETs prior to the etching 
process. The resulting ISFET structure is shown in 
Fig. 4 (b), (iii), illustrating elements located in the odd columns 
of Fig. 2. 
The fabricated CMOS chip is shown in Fig. 6, including 
photomicrographs detailing one of its array elements and the 
results of post-processing.  
IV. OPTICAL, ELECTRICAL AND ELECTROCHEMICAL 
PERFORMANCE OF CHIP 
All of the sensor types on the chip were independently 
evaluated. Since arrays of sensors were used, device-to-device 
variability known as fixed pattern noise (FPN) is expected [38]. 
For an imaging device FPN manifests itself as reduced picture 
quality. In addition to FPN, thermal noise is predominant in 
ISFETs and shot noise is predominant in the PDs and SPADs 
[39], [40]. In this work we do not want image data hence we 
have exploited the array to average all the signals from each 
sensor array to produce a single measurement with reduced 
noise [41]. The averaging process reduces the standard 
deviation of the overall measurement since the noise sources 
have a Gaussian distribution for large populations [42].  In 
addition to averaging over the different sensors used in each 
sensor array, we also sampled each sensor in a frame multiple 
times over a time interval, and averaged these too so as to 
produce a single measurement. Frame averaging in time 
intervals where events are relatively static has already been 
proven to improve noise in sensor data processing [43], [44]. 
Since the PD circuit is operated using a non-zero bias voltage, 
an offset is determined from the first measured frame; the same 
offset voltage is removed from all subsequent frames prior 
time-averaging [45], [46]. The method is also used for the 
ISFET. In an analogous method, the count rate from the first 
frame measured from the SPAD is used as a datum reference. 
To evaluate the ISFET pH sensitivity, the chip was tested 
with five buffer solutions with pH values 5, 6, 7, 8 and 9. A 
silver/silver chloride (Ag/AgCl) reference electrode was used 
biased at ~1.3 V with respect to the ISFET source voltage. Prior 
to testing the sensor, the chip was washed with DI water, dried 
with N2 and then tested in the pH 9 buffer to establish a baseline. 
Variations in the measured voltage from 3 devices were 
equalized for the measurement at pH 9 in order to measure the 
relative change in voltage with decreasing pH in subsequent 
measurements. The test was repeated using the remaining 
buffers in order of descending pH. The data from the three 
ISFETs was averaged using 500 samples per pH point per 
device. The data showed a pH sensitivity of 33 mV/pH with a 
linear response between pH 5 and pH 9 as shown in Fig. 7 (a) 
when tested against a commercial pH probe (HI5522, HANNA 
instruments, Italy). 
To test the dynamic range of the optical devices a 
monochromator was configured at a wavelength of 550 nm and 
attached to an optical integrating sphere to ensure uniform light 
distribution. An optical power meter (1936-R, Newport, USA) 
was fitted to one exit port to measure the light intensity. The 
CMOS chip was placed at another exit port. PD and SPAD 
sensor arrays were sampled for 100 frames each and averaged. 
In dark conditions, the output of the PD was 408 mV ± 22 mV. 
By gradually increasing the light intensity, the minimum 
detectable optical power density for the photodiode was 
measured at 50 nW/cm2 using the method described by Dandin 
and Abshire [47]. The PD signal started to saturate when 
exposed to 4.9 µW/cm2. The SPAD dynamic range was 
measured similarly and with the same single-wavelength light 
source. The SPAD array was activated and biased at 21.5 V (i.e. 
3 V above its breakdown voltage). The optimum values of 
quenching voltage, Vq, and comparator threshold voltage, Vtrig, 
were determined experimentally to be 1.20 V and 0.60 V 
respectively. In dark conditions, the SPAD produced a dark 
count rate (DCR) of 10 kcps ± 9.4 kcps. By gradually 
 
Fig. 6 Photomicrograph of the multimodal 16 x 16 element array chip, with 
(right) a magnified photomicrograph of a single element incorporating ISFET, 
PD and SPAD and (left) photomicrographs showing postprocessed elements 
where nanodiscs were fabricated selectively on alternate columns.  
  
TABLE I 
SENSOR CHARACTERISATION PARAMETERS 
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increasing the light intensity, the minimum detectable optical 
power density for the SPAD was 450 pW/cm2. The SPAD 
started to saturate with its output dominated by unwanted after-
pulsing at a maximum detection rate of 15.3 Mcps 
corresponding to 600 nW/cm2. 
The results show that the SPADs can detect substantially 
lower light levels than the PDs, making SPADs suitable for 
applications with low illumination intensity that require high 
sensitivity. In a complementary manner, the PDs are suitable 
for applications with high illumination intensity requiring less 
sensitivity. Together, they maximize the flexibility of the 
CMOS chip. The measured dynamic range of PD and SPAD 
arrays at 550 nm are reported in Fig. 7(a) and detailed in 
Table I.  
The signals from an unpatterned PD sub-array and a PD sub-
array with nanodiscs, each with 25 pixels, were measured over 
the optical band 400 - 900 nm. As can be seen both the devices 
show a peak voltage at approximately 630 nm, but only the 
device with nanodiscs shows an additional SPR minimum at 
785 nm (Fig. 7(c)). Similarly, a pair of SPAD sub-arrays with 
128 pixels, without and with added nanodiscs, show a peak at 
approximately 630 nm. The SPADs with nanodiscs show a 
minimum at 780 nm (Fig. 7 (d)). 
The post-processing for the nanodiscs alters the overall 
apparent sensitivity of the arrays as a consequence of the well-
known E-field field enhancement characteristics at resonance  
[48]. A small discrepancy between the PD and SPAD sensors 
with nanodiscs is a consequence of slight process variation. 
Because the nanodisc arrays require post-processing steps 
including electron beam lithography, metal deposition and lift-
off, there may be some modification to PD and SPAD 
characteristics, the detailed study of which are outside the scope 
of this paper. Direct comparison of the measured transmission 
data shown in Fig. 5 is not possible for the chip since the silicon 
is not transparent. However, the PD and SPAD data clearly 
show spectral characteristics with the same main features. 
The benefits of averaging for arrays of sensors as a function 
of the number of sensor pixels is illustrated in Fig. 8. It can be 
seen that the standard deviation that represents the signal noise, 
measured in volts, or in the case of the SPADs, cps, decreases 
as the number of pixels increases. The averaging process 
reduced the noise as a function of N-1/2, where N is the number 
of sensors, as expected for Gaussian noise sources. 
V. DIAGNOSTIC PLATFORM 
A complete diagnostic platform was implemented to enable 
biological experiments and to demonstrate a diagnostic point of 
care prototype for rapid biomarker detection. The platform 
consists of a disposable cartridge, a reader for data acquisition 
and control and a portable computer to visualize the results. The 
cartridge comprises the CMOS chip and a ceramic pin grid 
array chip carrier (CPGA 120, Spectrum Semiconductor 
Materials Inc., USA). The chip was fabricated using a high-
voltage CMOS process (H35, Austria Microsystems, Austria).  
A biocompatible epoxy (EPO-TEK H74, Epoxy Technology 
Inc., USA) was used to protect the chip wire-bonds and to fix a 
culture ring around the chip for aqueous measurements in a 
cavity created on the chip’s surface, using the procedure 
detailed in [37]. The reader incorporates a printed circuit board 
(PCB) to host the post-processed chip and an ARM Mbed 
microcontroller (STM32 Nucleo-F334R8, STMicroelectronics, 
UK). The Mbed microcontroller is programmed to provide 
addressing signals and to acquire output readings from the 
arrays. A 12-bit analog-to-digital converter (ADC) incorporated 
in the Mbed converts the analog PD and ISFET sensor output 
readings to digital signals. This digital data along with the 
SPAD digital outputs are transferred via USB to a laptop in 
which they are processed and analysed via a LabVIEW 
application (National Instruments, Austin, TX, USA). The USB 
link also provides power for the chip and Mbed microcontroller. 
The complete diagnostic platform used in this work is shown in 
 
Fig. 8. Standard deviations of averaged measurements as functions of the 
number of sensors for the SPAD array, PD array and ISFET array 
 
Fig. 7. Characterization and performance evaluation of the CMOS platform.  
(a) Measured characterization of the ISFET sensor showing an output 
voltage which is a linear function of pH with a sub-Nernstian slope of 
33 mV/pH. (b) Measured extended optical dynamic range of the SPAD and 
the PD. (c) Response of PD with nanodiscs shows a dip at ~785 nm. (d) 
Count rate of SPAD with nanodiscs shows a dip at ~780 nm. 
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Fig. 9. Its timing diagram for one frame acquisition is illustrated 
in Fig. 10.  
VI. BIOLOGICAL EXPERIMENTS 
We performed experiments for metabolite detection to prove 
the chip’s capabilities in its various sensing modes. Urate, 
cholesterol and urea-urease metabolites were used for 
chemiluminescence, colorimetric and H+ measurement modes. 
Instead of showing reaction rates [49], [50] real time 
measurement signals were plotted to demonstrate the 
performance of each sensor. The SPR mode was demonstrated 
with glycerol. In addition to single mode measurements, we 
also showed that the platform can detect two metabolites 
simultaneously, using glucose and cholesterol. The 
implemented diagnostic platform was used and in the 
configured setup shown in Fig. 11 to conduct the biological 
experiments. The reference electrode used for a modality 
measurement that involves the ISFET array whereas the 
monochromator was used for colorimetric and SPR 
measurements.  
A. Chemiluminescence mode 
The chemiluminescence mode was demonstrated by 
detecting uric acid. A low level of this metabolite in human 
blood is an indication of Parkinson’s disease[51] and elevated 
levels can be a risk indicator for cardiovascular, kidney disease 
and acute gout. In a chemiluminescent assay, luminol must be 
activated with an oxidant, which is usually a solution containing 
hydrogen peroxide (H2O2). In this study, a uric acid-uricase 
enzymatic reaction was used to produce H2O2. Prior to the 
measurement, the chip was cleaned with acetone and isopropyl 
alcohol (IPA). Then a solution comprising 900 µL of 100 µM 
uric acid in 50 mM triethanolamine pH 8.5, 50 µL of 60 
units/mL peroxidase enzyme solution, and 50 µL of 8mM 
luminol solution was placed onto the sensor surface. After a 
stable baseline was obtained, 50 µL of 1 units/mL uricase 
enzyme solution was added to initiate the reaction. The blue 
glow from the reaction was detected by the SPAD. The 100 µM, 
500 μM and 1 mM concentrations of uric acid were used to 
cover the physiological ranges, 208 - 428 µM for males and 
155 - 357 µM for females[52]. Fig. 12 (a) shows the reaction 
curves of the two concentrations and a control baseline.  
 
 
Fig. 11. Setup used to validate the use of the CMOS platform for different 
modalities.  
 
Fig. 10.  System timing diagram of a single frame acquisition for PD, SPAD 
and ISFET array. The reported required times for data processing and 
visualization are average values that are dependent on the speed of the 
device (i.e laptop, tablet or phone) used. 
 
Fig. 9. A photograph of the diagnostic platform that includes the disposal 
unit, reader and laptop for visualization of the acquired results. 
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B. Colorimetric mode 
The colorimetric mode was demonstrated by the detection of 
a cholesterol metabolite in human serum; a high level is 
indicative of cardiovascular disease[53]. Detecting this 
metabolite depends on H2O2 which is commonly generated in 
many enzymatic assay reactions. When combined with 
peroxidase and redox colour-change indicators, the rate of the 
evolution of H2O2 can be detected by the PD array. Cholesterol-
cholesterol oxidase reaction was undertaken to produce H2O2.  
Prior to the measurement, the chip was cleaned with acetone 
and IPA. Then a solution comprising 830 µL of 20 mM 
triethanolamine pH 8.5, 40 µL of 10 mM cholesterol with 
10% (w/v) triton X-100, 50 µL of 60 units/mL peroxidase 
enzyme solution, and 40 µL of 7.89 mM o-Dianisidine solution 
was placed onto the sensor surface. After a stable baseline was 
obtained, 40 µL of 10 units/mL cholesterol oxidase enzyme 
solution was added to initiate the reaction. The reaction 
generated a brown colour that was detected by the PD 
illuminated with a green light from a monochromator at 
500 nm.  
Concentrations of 625 µM, 5 mM and 10 mM were used to 
cover the physiological range, which is below 5.17 mM [54]. 
The reaction curves of the two concentration levels and the 
control baseline are shown in Fig. 12 (b).  
C. Hydrogen ion measurement mode 
The hydrogen ion measurement mode was demonstrated 
using urea-urease which is an important compound in metabolic 
processes; a high concentration in blood is a significant 
indicator of renal and heart diseases [55]. The urea-urease 
metabolic activity tends to increase the H+ ion concentration of 
its solution as it produces ammonia, which is a basic molecule. 
Therefore, the urea-urease reaction was used for ISFET studies. 
 
 
Fig. 12. Biological experiments results. (a) SPAD array response as a function of three different urate concentrations, with control experiment response.  (b) PD 
array response for different cholesterol concentrations. (c) ISFET array response for different urea-urease concentrations. (d) PD response as a function of change 
in refractive index: glycerol concentrations of (0 - 100%) were measured with recorded sensitivity of 5.3 V/ RIU and resolution of 2.2 x 10-4 RIU.  (e) SPAD 
response as a function of change in refractive index. The SPAD has a higher sensitivity of 7.3 Mcps/RIU which corresponds to a resolution of 3.8 x 10-5 RIU. (f) 
Real-time detection of three concentrations of human serum samples and one control sample. The signals derived from the glucose-hexokinase (red curves) and 
cholesterol-cholesterol oxidase (blue curves) interactions were recorded simultaneously by the ISFET and PD sensors. In (a), (b), (c) and (f), the yellow area 
indicates time until the serum sample was added. 
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Prior to measurement, the chip was cleaned with acetone and 
IPA. The potential of the Ag/AgCl reference electrode was set 
to 0 V. To start the experiment, 950 µL of 30 mM urea in 50 
mM triethanolamine pH 8.5 was firstly placed on the sensor 
surface. After a stable baseline was obtained, 50 µL of 80 
units/mL urease enzyme solution was added to initiate the 
reaction. A decrease of the voltage signal was detected by the 
ISFET. Similarly to the previous metabolites, the three 
concentrations of urea-urease, at 2 mM, 15 mM and 30 mM, 
were used to bracket the physiological range, 4.98 - 6.64 mM. 
The results, including a control baseline, are shown in 
Fig. 12 (c). The long-term pH drift was measured to be 0.8 
mV/hour [37] which is negligible compared to the actual 
measurement signal. 
D. Surface plasmon resonance mode 
SPR sensors on chip were used to demonstrate that the 
detected signal varied in response to changing the local 
refractive index around the metal structures. Experiments were 
performed using glycerol in water. The refractive index of 
glycerol in water as a function of the glycerol concentration is 
well-known [31]. Variation in refractive index is measured in 
refractive index units (RIU). As it can be seen in Fig. 7(c), the 
SPR structure introduces a minimum in the spectral response 
measured by the PD or SPAD at 780 nm.  In this experiment a 
monochromator is set to emit at 780 nm, and the PD or SPAD 
signal is recorded as a function of the variation in the glycerol 
concentration, or refractive index. In this manner the SPR 
structure’s response to varying refractive index is measured on-
chip, analogous to the demonstration on glass shown in Fig. 5. 
Figs. 12 (d) and (e) show the light intensity as a function of 
the refractive index change for the PD and SPAD with 
nanodiscs, respectively. In each case an offset has been 
introduced such that zero corresponds to the voltage or count 
rate in the presence of pure water. The graphs show the change 
in signal observed with varying refractive index. For the PD 
device we measured a signal change of 5.3 V/RIU and a 
resolution of 2.2 x 10-4 RIU. For the SPAD we observe a change 
in count rate of 7.3 Mcps/RIU, and we were able to resolve a 
change in refractive index of 3.8 x 10-5 RIU. Measurements 
from a PD and a SPAD without nanodiscs exhibited 
insignificant sensitivity to variation in the refractive index. 
Unlike other modalities provided by the chip, measurements 
from the nanodisc functionalised sensors were taken from a 
single sensor in the array. The experiment was repeated three 
times and averaged. The sample interval for the PD 
measurement was 0.20 s and 1 second for the SPAD. 
E. Simultaneous Metabolite Detection in Human Serum 
Detecting more than one metabolite simultaneously provides 
another demonstration of the added value of the platform. To 
demonstrate this, we developed an assay in which cholesterol 
and glucose are detected simultaneously in human serum. Two 
human serum samples and one control sample (without 
cholesterol or glucose) were detected by the ISFET and PD 
individually. Serum cholesterol and glucose can be detected and 
quantified by the two sensors simultaneously and 
independently. Human serum with 5 mM cholesterol and 4 mM 
glucose was diluted by a factor of 2 and 8 to give 2.5 mM, 625 
μM cholesterol and 2 mM, 500 μM glucose.   
The reaction buffer was prepared by mixing together the 
following enzymes and chemicals which are required for 
simultaneous glucose and cholesterol detection measurements: 
46.9 µL of 5mM triethanolamine HCl at pH 8, 1.7 µL of 
15% w/w taurocholic acid solution, 1.7 µL of 15% w/w cholic 
acid solution, 5 µL of 60units/mL peroxidase, 10 µL of 500 mM 
NaCl, 1.7 µL of 8.5 units/mL cholesterol esterase, 10 µL of 
100 mM MgCl2 solution, 10 µL of 100 mM ATP pH8.5, 4 µL 
of 7.89 mM o-Dianisidine, 1 µL of 0.1 units/µL hexokinase, 
and 3 µL of 10 units/mL cholesterol oxidase. 
The reaction buffer was added to the sensing well at time 
considered as t = 0 to obtain baselines for both the ISFET and 
PD. The human serum sample was added to initiate the 
reactions. Both the ISFET and PD generated signal changes 
immediately. The enzymatic reactions were measured through 
the change in voltage as a function of time. 
As in previous measurements, the concentrations covered the 
physiological ranges of both metabolites [56]. Fig. 12 (f) shows 
the results for the high and low concentrations of both 
metabolites detected simultaneously.  
A control baseline was established with a buffer solution for 
experiments conducted in this Section. The lowest detectable 
concentration in each experiment was chosen to be higher than 
3.5 times the standard deviation of the control baseline, set as 
the limit of detection (LOD).  
VII. CONCLUSION 
The ability to rapidly detect multiple metabolites using the 
same instrument has a potential to reduce diagnosis time and its 
cost. CMOS technology allows for the integration of different 
types of sensors on a single chip to achieve this function, 
replacing large, expensive laboratory systems. For the first time 
we show that multi-sensor elements can be used to create a 
multimodal sensor on a single CMOS chip for use in 
biochemical assay by analysing correlated data. In addition to 
incorporating ISFETs to detect proton release in enzymatic 
assays, each element of the array format chip contains a 
photodiode and a SPAD. Uniquely, by integrating these two 
optical sensor types, it is possible to extend the dynamic range, 
hence utility, of the device by 1.5 decades. Each optical sub-
array was further functionalized by the addition of gold 
nanodiscs to introduce an SPR modality. Altogether, the system 
enables chemiluminescence, colorimetric, SPR based and 
electrochemical measurements of the same analyte, all of which 
have been experimentally evaluated. The system’s ability to 
quantify urea, cholesterol and urate within the human 
physiological range was demonstrated. Quantification of 
glycerol in a solution with water was also demonstrated to 
validate SPR sensing. With five physical sensors, each of which 
can be biofunctionalized independently, we have demonstrated 
a highly capable route towards a comprehensive point-of-care 
metabolomic test system for use in medical diagnostics. 
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